Handelsavisen
prelaunch
Companies ›Healthcare ›CTMX
CT
CTMX — Nasdaq Biotechnology

CytomX Therapeutics, Inc.

$3,17
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
562,0M USD
P/E
—
EV / Rev
7,0x
Div yield
—
Op margin
-29,3 %
ROE
-5,4 %
Net margin
-22,8 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$3,25
Open
$3,25
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

CytomX Therapeutics operates as a clinical-stage biopharmaceutical company developing targeted immunotherapies, generating revenue primarily through collaboration and license agreements with partners such as Amgen, Bristol-Myers Squibb, and Regeneron.

Business. CytomX Therapeutics, Inc. (Nasdaq: CTMX) is a biotechnology company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. As segment and geographic breakdowns are not specified, the company is described at the industry level as a biotechnology entity.

Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
BUY8 analysts
8 buy0 hold0 sell
Avg 12m price target12,57

Analyst recommendations

8 analysts · consensus Buy
Buy8
Hold0
Sell0
12-month price target
12,57
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
8 analysts · indicative
Ownership→
FMR LLC
largest disclosed fund holder
Profitability→
-5,4 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning CTMX.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to CTMX. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    CytomX Therapeutics, Inc. (Nasdaq: CTMX) is a biotechnology company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. As segment and geographic breakdowns are not specified, the company is described at the industry level as a biotechnology entity.

    Classification85 %
    SectorHealth Care
    Industry groupBiotechnology
    AI synthesis
    GENERATED

    CytomX maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a robust current ratio of 10.38, indicating strong short-term liquidity coverage. Total equity stands at $319.9 million, supported by $28.8 million in cash and equivalents as of Q1 2026. The company recently completed an underwritten public offering in March 2026, issuing approximately 46 million shares and pre-funded warrants, which significantly expanded its cash reserves but also increased the share count. The market capitalization is approximately $562.8 million, trading at a price-to-book ratio of 1.76.

    Profitability remains negative, with a net loss of $18.2 million and an operating loss of $19.7 million in Q1 2026. Return on equity is -5.43% and return on assets is -4.83%, reflecting the pre-commercial stage of the business. Operating cash flow was negative $25.5 million, with no capital expenditures recorded, resulting in identical free cash flow. The company generates minimal organic revenue, reporting $10.3 million in Q1 2026, leading to a negative EV/EBITDA multiple of -23.88 and an EV/Revenue multiple of 7.01.

    Revenue is derived from collaboration and license agreements rather than product sales, with key partners including Amgen, Astellas Pharma, Bristol-Myers Squibb, and Regeneron Pharmaceuticals. The company also has agreements with ModernaTX and ImmunoGen. Geographic exposure is primarily domestic, as indicated by the presence of domestic country members in the filing data. The revenue mix is heavily concentrated in these partnership milestones and license fees, with no disclosed product revenue streams.

    Growth trajectory is characterized by high volatility in share count and capital raises rather than organic revenue expansion. The basic share count increased from 80.6 million in Q1 2025 to 170.2 million at the end of 2025, and further to 217.7 million by Q1 2026 following the recent offering. Revenue in Q1 2026 was $10.3 million, but historical annual revenue trends are not provided in the input data to assess long-term growth rates. The company's financial history shows a transition from a stockholders' deficit of $0.5 million in Q1 2025 to equity of $319.9 million in Q1 2026, driven by capital raises.

    Risk factors include high dilution risk, as evidenced by the significant increase in shares outstanding and the presence of pre-funded warrants and options. The diluted share count is moderately above the basic share count, and source documents explicitly mention dilution or offering risk. Liquidity risk is assessed as low due to the strong current ratio and recent capital infusion. Key flags indicate that the company relies on external funding and partnership milestones to sustain operations.

    Recent events include the completion of an underwritten public offering in March 2026, raising net proceeds of approximately $234 million from the issuance of common stock and pre-funded warrants. An 8-K filing was submitted with high severity regarding material events. Analyst sentiment is positive, with a mean recommendation of 1.50 (strong buy) and a mean price target of $12.57, significantly above the current market price of $3.175. The company also reported one-time severance payments and other employee-related costs in 2025.

    Key takeaways
    • CytomX maintains a strong balance sheet with $319.9 million in equity and a 10.38 current ratio, mitigating near-term liquidity risk.
    • High dilution risk is present due to a recent 46 million share offering and outstanding pre-funded warrants, increasing the share count to 217.7 million.
    • The company remains unprofitable with a Q1 2026 net loss of $18.2 million and negative operating cash flow of $25.5 million.
    • Revenue is dependent on collaboration agreements with major pharma partners like Amgen, BMS, and Regeneron, with no product sales.
    • Analyst consensus is strongly bullish with a mean price target of $12.57, implying significant upside from the current $3.175 price.
    • The company has no debt, providing financial flexibility but relying on equity financing for growth.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    CytomX achieved $138.1 million in FY2024 revenue, representing an 81.2% year-over-year growth rate.

    The company reported $31.9 million in net income for FY2024, a 283.5% increase from the prior period.

    CytomX maintains a low leverage band with a debt-to-equity ratio of 0.53 as of late 2025.

    Return on equity of -5.43% ranks above the biotechnology cohort median of -23.83%.

    The firm holds a current ratio of 3.09, indicating strong short-term liquidity coverage.

    BEAR CASE · 2

    CytomX faces high dilution risk, which could significantly erode shareholder value in future financing rounds.

    FY2025 revenue is projected to drop to $76.2 million, reversing recent growth trends.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-31
    Q4 2025 · Quarter highlights

    Revenue $10.3M; Operating income -$19.7M.

    Revenue$10.3M
    Operating income-$19.7M
    Net income-$18.2M
    Free cash flow-$25.5M
    EPS—
    Operating cash flow-$25.5M
    Financials
    Income statement
    Revenue$10.3M
    Gross profit—
    Operating income-$19.7M
    Net income-$18.2M
    Margins
    Gross margin—
    Operating margin-191.8%
    Net margin-177.9%
    FCF margin-249.1%
    Balance sheet
    Total assets$359.4M
    Total liabilities$39.4M
    Total equity$319.9M
    Cash & equivalents$28.8M
    Long-term debt—
    Cash flow
    Operating cash flow-$25.5M
    CapEx$0.00
    Free cash flow-$25.5M
    SBC$4.7M
    P&L flow · revenue → net income
    Revenue $10.3MOperating costs $29.9MNet income $18.2M
    Highlights
    • ▍Revenue $10.3M
    • ▍Operating income -$19.7M
    • ▍Net margin -177.9%

    Valuation FY

    Market price
    $3,17
    Market cap
    $562.8M
    Enterprise valueⓘ
    $534.0M
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    7.0x
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    1.8x
    P / Tangible bookⓘ
    1.8x
    Tangible book
    $319.0M
    Net cashⓘ
    $28.8M
    Current ratioⓘ
    10.4
    Debt / equityⓘ
    —
    ROAⓘ
    -4.8%
    ROEⓘ
    -5.4%
    Cash conversionⓘ
    435.0%
    CapEx / revenueⓘ
    0.3%
    SBC / revenueⓘ
    8.3%
    Dilution ratioⓘ
    4.2%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships7 disclosed relationships · 1 type · extracted from filings & disclosures
    Partners7
    AMGEN INC.AMGN.OPartner95%Source ↗
    MERCK & CO., INC.MRK.OPartner95%Source ↗
    MODERNA, INC.MRNA.OPartner95%Source ↗
    Abbvie IncABBV.KPartner85%Source ↗

    Supply chain

    Vendors → CTMX ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSCTMXCTMXCytomX Therapeutics, Inc.7 entitiesAMGEN INC.PharmaceuticalsUSAstellas Pharma IncPharmaceuticalsJPBristol-myers Squibb CPharmaceuticalsUSMERCK & CO., INC.USMODERNA, INC.Diversified PharmaceuticUSREGENERON PHARMACEUTICDiversified PharmaceuticUSAbbvie IncPharmaceuticalsUS
    7 mentions in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,42
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    8
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-07-28 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate-0,42
    Revenue—no estimate—no estimate36,5M USD
    Operating income—no estimate—no estimate-87,5M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution8 analysts
    Strong buy4
    Buy4
    Hold0
    Sell0
    Strong sell0
    12-month price target$12,57 · Median $12,00
    Low $6,00High $16,00
    Operating income · consensus-87,5M USD
    EPS surprise
    +64,0 %
    reported vs consensus · beat
    Revenue surprise
    +108,9 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$6,00
    Mean$12,57
    Median$12,00
    High$16,00
    Spot$3,17
    +296.6 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskHigh
    Liquidity riskLow
    Filing-based flags
    • Diluted share count is moderately above the basic share count.
    • Source documents mention dilution or offering risk.

    Benchmarks vs cohort

    Op Margin-29,3 %Above median
    Net Margin-22,8 %Above median
    ROE-5,4 %Above P75
    Capex / Rev0,3 %Above median
    D/E0,00Above median
    Cash Conv4,35Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 4 294 100 sh23 grants13 insiders
    • Fuchs Charles S.Director · Stock Option (Right to Buy) → Common StockAcquired 118 000 @ $3,24grant · 2026-07-24
    • Young Matthew P.Director · Stock Option (Right to Buy) → Common StockAcquired 59 000 @ $2,96grant · 2026-06-17
    • Jones Elaine VDirector · Stock Option (Right to Buy) → Common StockAcquired 59 000 @ $2,96grant · 2026-06-17
    • Ashworth AlanDirector · Stock Option (Right to Buy) → Common StockAcquired 59 000 @ $2,96grant · 2026-06-17
    • Gilbert Halley EDirector · Stock Option (Right to Buy) → Common StockAcquired 59 000 @ $2,96grant · 2026-06-17
    • Meyers James RDirector · Stock Option (Right to Buy) → Common StockAcquired 59 000 @ $2,96grant · 2026-06-17
    • Mohindru ManiDirector · Stock Option (Right to Buy) → Common StockAcquired 59 000 @ $2,96grant · 2026-06-17
    • Su ZhenDirector · Stock Option (Right to Buy) → Common StockAcquired 59 000 @ $2,96grant · 2026-06-17
    • Chu Yu-WayeChief Medical Officer · Stock Option (Right to Buy) → Common StockAcquired 300 000 @ $6,09grant · 2026-02-02
    • Lester RachaelChief Business Officer · Stock Option (Right to Buy) → Common StockAcquired 50 000 @ $6,09grant · 2026-02-02
    • Lester RachaelChief Business Officer · Performance Stock Units (PSUs) → Common StockAcquired 50 000grant · 2026-02-02
    • BELVIN MARCIASVP, Chief Scientific Officer · Stock Option (Right to Buy) → Common StockAcquired 250 000 @ $6,09grant · 2026-02-02
    • McCarthy Sean A.Director, CEO · Stock Option (Right to Buy) → Common StockAcquired 980 000 @ $6,09grant · 2026-02-02
    • Ogden ChristopherChief Financial Officer · Stock Option (Right to Buy) → Common StockAcquired 325 000 @ $6,09grant · 2026-02-02
    • Lester RachaelChief Business Officer · Stock Option (Right to Buy) → Common StockAcquired 650 000 @ $3,74grant · 2025-10-20
    • McCarthy Sean A.Director, CEO · Stock Option (Right to Buy) → Common StockAcquired 570 000 @ $2,90grant · 2025-09-26
    • Ogden ChristopherChief Financial Officer · Performance Stock Units (PSUs) → Common StockAcquired 39 150grant · 2025-09-26
    • Ogden ChristopherChief Financial Officer · Stock Option (Right to Buy) → Common StockAcquired 78 250 @ $2,90grant · 2025-09-26
    • Chu Yu-WayeChief Medical Officer · Performance Stock Units (PSUs) → Common StockAcquired 43 750grant · 2025-09-26
    • Chu Yu-WayeChief Medical Officer · Stock Option (Right to Buy) → Common StockAcquired 87 500 @ $2,90grant · 2025-09-26
    • McCarthy Sean A.Director, CEO · Performance Stock Units (PSUs) → Common StockAcquired 285 000grant · 2025-09-26
    • BELVIN MARCIASVP, Chief Scientific Officer · Stock Option (Right to Buy) → Common StockAcquired 36 300 @ $2,90grant · 2025-09-26
    • BELVIN MARCIASVP, Chief Scientific Officer · Performance Stock Units (PSUs) → Common StockAcquired 18 150grant · 2025-09-26

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Regulatory filings
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Price To Tangible Book
      market_price / (tangible_book_value / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Return On Equity
      net_income / total_equity
    • Enterprise Value
      market_cap - net_cash
    • Ev To Revenue
      enterprise_value / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    Source documents
    • CytomX Therapeutics, Inc. company facts · 2026-07-28
    • CytomX Therapeutics, Inc. 10-Q 2026-05-07 · 2026-07-28
    • CytomX Therapeutics, Inc. 10-K 2026-03-16 · 2026-07-28
    • CytomX Therapeutics, Inc. 10-Q 2025-11-06 · 2026-07-28
    • CytomX Therapeutics, Inc. 10-Q 2025-08-07 · 2026-07-28
    • 8-K (sec_8k_material) on CTMX · 2026-07-28
    • CytomX Therapeutics Inc Market data — analyst estimates · 2026-07-28
    • CytomX Therapeutics Inc Market data — ESG · 2026-07-28
    • CytomX Therapeutics, Inc. HA canonical relationships · 2026-07-28

    Ownership & reference

    Top holders

    • FMR LLCInstitutional Investor · as of 2026-03-310,01 %$150M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$17M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$15M
    • First Trust Advisors L.P.Investment Managers · as of 2026-03-310,00 %$3M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$9M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$27M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$7M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$10M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$2M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$36M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$3M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$1M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$2M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$0M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$0M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$0M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$1M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M

    Leadership

    • Sean A. McCarthyChairman of the Board, Chief Executive Officer

    Insider activity

    Net selling0 buys · 6 sellsnet -$1,7M5 insiders · last 365d
    • Ogden ChristopherChief Financial Officer · Common StockSold 1 624 @ $3,05$5K · 2026-06-15
    • Chu Yu-WayeChief Medical Officer · Common StockSold 21 279 @ $6,42$137K · 2026-03-17
    • McCarthy Sean A.Director, CEO · Common StockSold 118 969 @ $6,42$764K · 2026-03-17
    • BELVIN MARCIASVP, Chief Scientific Officer · Common StockSold 31 492 @ $6,42$202K · 2026-03-17
    • Ogden ChristopherChief Financial Officer · Common StockSold 19 323 @ $6,42$124K · 2026-03-17
    • Lester RachaelChief Business Officer · Common StockOther 20 000 · 2026-02-02
    • Chu Yu-WayeChief Medical Officer · Common StockOther 75 000 · 2026-02-02
    • BELVIN MARCIASVP, Chief Scientific Officer · Common StockOther 60 000 · 2026-02-02
    • Ogden ChristopherChief Financial Officer · Common StockOther 90 000 · 2026-02-02
    • McCarthy Sean A.Director, CEO · Common StockOther 210 000 · 2026-02-02
    • McCarthy Sean A.Director, CEO · Class A Common StockSold 101 793 @ $4,54$462K · 2025-11-06

    Short positioning

    40.3Mshares short+13.4% vs prior
    10.38days to cover
    68.3%short of daily vol
    3.0Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    CTMXCanonical
    Nasdaq · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskHigh
    Liquidity riskLow
    Diluted share count is moderately above the basic share count.
    Source documents mention dilution or offering risk.
    Relationship graph
    CTMXAMGN.O4503.TBMY.OMRK.OMRNA.OREGN.OABBV.KBiotechnology
    This companySectorPartners

    Evidence & claims

    From filings & derived data
    • Shares outstanding (annual): 170.19MUnknown
    • Total liabilities (annual): USD 52.56MUnknown
    • Revenue (annual): USD 76.2MUnknown
    • R&D expense (annual): USD 68.73MUnknown
    • Pre-tax income (annual): USD -17.13MUnknown
    • Current liabilities (annual): USD 46.62MUnknown
    • Capex (annual): USD 220KUnknown
    • Total assets (annual): USD 151.57MUnknown
    • Net income (annual): USD -17.37MUnknown
    • Operating income (annual): USD -22.36MUnknown
    • Shareholders' equity (annual): USD 99.01MUnknown
    • Total operating expenses (annual): USD 98.56MUnknown
    • Current assets (annual): USD 143.92MUnknown
    • Operating cash flow (annual): USD -75.59MUnknown
    • Cash & equivalents (annual): USD 12.67MUnknown
    • Total liabilities (annual): USD 120.99MUnknown
    • Current liabilities (annual): USD 85.77MUnknown
    • Revenue (annual): USD 138.1MUnknown
    • Pre-tax income (annual): USD 32.09MUnknown
    • Current assets (annual): USD 107.31MUnknown
    • Capex (annual): USD 310KUnknown
    • R&D expense (annual): USD 83.38MUnknown
    • Operating cash flow (annual): USD -86.23MUnknown
    • Net income (annual): USD 31.87MUnknown
    Showing 24 of 30 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-28 04:34 UTCFILINGMaterial 8-K
    2026-07-24INSIDERFuchs Charles S. acquired 118.0k sh Stock Option (Right to Buy) — Director
    2026-06-17 00:00 UTCINSIDER8 insider transactions — 2026-06 7 derivative
    2026-06-17 00:00 UTCINSIDER8 insider transactions — 2026-06 7 derivative
    2026-06-17INSIDERJones Elaine V acquired 59.0k sh Stock Option (Right to Buy) — Director
    2026-06-17INSIDERSu Zhen acquired 59.0k sh Stock Option (Right to Buy) — Director
    2026-06-17INSIDERYoung Matthew P. acquired 59.0k sh Stock Option (Right to Buy) — Director
    2026-06-17INSIDERMeyers James R acquired 59.0k sh Stock Option (Right to Buy) — Director
    2026-06-17INSIDERMohindru Mani acquired 59.0k sh Stock Option (Right to Buy) — Director
    2026-06-17INSIDERGilbert Halley E acquired 59.0k sh Stock Option (Right to Buy) — Director
    2026-06-17INSIDERAshworth Alan acquired 59.0k sh Stock Option (Right to Buy) — Director
    2026-06-15INSIDEROgden Christopher sold 1.6k sh — Chief Financial Officer ~$5k
    2026-06-03FILING8-K filing →
    2026-05-07FILING8-K filing →
    2026-05-07FILING10-Q filing →
    2026-04-30FILINGDEF 14A filing →
    2026-03-31EARNINGSQuarterly results — Q4 2025 Revenue USD 10.3M · Net USD -18.2M
    2026-03-19FILING8-K filing →
    2026-03-18FILING424B5 filing →
    2026-03-17 00:00 UTCINSIDER4 insider transactions — 2026-03 · net sell $1.2M
    2026-03-17 00:00 UTCINSIDER4 insider transactions — 2026-03 · net sell $1.2M
    2026-03-17INSIDERChu Yu-Waye sold 21.3k sh — Chief Medical Officer ~$137k
    2026-03-17INSIDERMcCarthy Sean A. sold 119.0k sh — Director, CEO ~$764k
    2026-03-17INSIDERBELVIN MARCIA sold 31.5k sh — SVP, Chief Scientific Officer ~$202k
    2026-03-17INSIDEROgden Christopher sold 19.3k sh — Chief Financial Officer ~$124k
    2026-03-16FILING424B5 filing →
    2026-03-16FILING8-K filing →
    2026-03-16FILING10-K filing →
    2026-02-02 00:00 UTCINSIDER11 insider transactions — 2026-02 6 derivative
    2026-02-02 00:00 UTCINSIDER11 insider transactions — 2026-02 6 derivative
    2026-02-02INSIDERLester Rachael transacted 20.0k sh — Chief Business Officer
    2026-02-02INSIDERChu Yu-Waye transacted 75.0k sh — Chief Medical Officer
    2026-02-02INSIDERBELVIN MARCIA transacted 60.0k sh — SVP, Chief Scientific Officer
    2026-02-02INSIDEROgden Christopher transacted 90.0k sh — Chief Financial Officer
    2026-02-02INSIDERMcCarthy Sean A. transacted 210.0k sh — Director, CEO
    2026-02-02INSIDERLester Rachael acquired 50.0k sh Stock Option (Right to Buy) — Chief Business Officer
    2026-02-02INSIDERChu Yu-Waye acquired 300.0k sh Stock Option (Right to Buy) — Chief Medical Officer
    2026-02-02INSIDERBELVIN MARCIA acquired 250.0k sh Stock Option (Right to Buy) — SVP, Chief Scientific Officer
    2026-02-02INSIDERMcCarthy Sean A. acquired 980.0k sh Stock Option (Right to Buy) — Director, CEO
    Showing the 40 most recent of 62 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage